Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Epcoritamab · Epkinly, GEN-3013

Bispecific antibody · Immune activation, directed at CD20 (MS4A1) and CD3 receptor (CD3E) · developed by Genmab Us

Approved FDA, May 2023
GMAB Developer
2 Registered trials

What is Epcoritamab?

Epcoritamab is a bispecific CD20-directed CD3 T-cell engaging antibody. It binds CD3 on T-cells and CD20 on B-lineage lymphoma cells, bringing the two together so T-cells lyse the B-cells. It is studied in B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Epkinly, GEN-3013, ABBV-GMAB-3013, DuoBody-CD3xCD20, EPKINLY
Drug type
Bispecific antibody
Targets
CD20 (MS4A1), CD3 receptor (CD3E)
Mechanism
Immune activation, directed at CD20 (MS4A1) and CD3 receptor (CD3E)
Pathways
T-cell activation, proinflammatory cytokine release, B-cell lysis, NK cell-mediated antibody-dependent cellular cytotoxicity
Therapy area
Oncology
Developer
Genmab Us, Inc. (GMAB)
FDA status
Approved as Epkinly (May 19, 2023), BLA761324 · FDA label
UNII
D6OMY2L0WA

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05578976 Phase 3 Diffuse Large B-Cell Lymphoma Active not recruiting GMAB
NCT04542824 Phase 1/2 Diffuse Large B Cell Lymphoma Active not recruiting GMAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Large B Cell LymphomaFollicular LymphomaHigh-grade B-cell LymphomaMarginal Zone LymphomaPrimary Mediastinal Large B Cell LymphomaSmall Lymphocytic Lymphoma

Other drugs acting on MS4A1 / CD3E

More from Genmab Us

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.

Follow GMAB, the company behind Epcoritamab

See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GMAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.